Compare Dollar Tree, Inc. (DLTR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Novo Nordisk A/S — how do they compare? Dollar Tree, Inc. trades at $118.61 (market cap $22.26B), while Novo Nordisk A/S trades at $38.17 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 7.4× Dollar Tree, Inc.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Novo Nordisk A/S for 116 Days on average.
| DLTR | NVO | |
|---|---|---|
Market Cap | $22.26B | $165.31B |
Volume | 2,317,428 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $63.98 |
52-Week Low | $86.80 | $35.29 |
Typical Hold Time | 58 Days | 116 Days |
Enterprise Value | $28.87B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.3, up slightly by 0.09% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $2.70 significantly exceeding the $1.15 estimate. Revenue for 2025 was $17.58 billion, though net income was negative due to a large tax expense, while 2026 projections indicate a return to profitability. Strategic initiatives like store expansions and a multi-price strategy are driving growth, supported by positive institutional buying activity.
The outlook for DLTR is positive, with a consensus price target of $139.33 offering ~20% upside. Key opportunities include continued earnings momentum and market share gains, but risks involve margin pressures from tariffs and rising costs. Investors should weigh the strong ROE of 45.87% against volatility in net income and competitive discount retail dynamics.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
